18 completed, 5 terminated, 1 unknown, 1 withdrawn. 25 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 18, Terminated 5, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow telaprevir: new trials by email Literature Review of telaprevir trials Research Report on telaprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 Telaprevir and Sofosbuvir - Hepatitis C, Chronic | Phase 2 | Completed | University of Florida | 20 | 2013-12-01 | 2018-04-23 |
| Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 Telaprevir, Peginterferon alfa-2a, Ribavirin - Hepatitis C | Phase 2 / Phase 3 | Withdrawn | Timothy Morgan, MD | 2013-08-01 | 2014-05-14 | |
| Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection Miravirsen, Telaprevir, Ribavirin - Hepatitis C, Chronic | Phase 2 | Unknown | Santaris Pharma A/S | 20 | 2013-06-01 | 2014-11-18 |
| Interaction Between Paroxetine and Telaprevir Paroxetine, telaprevir - Hepatitis C Infection, Depression | Phase 2 | Terminated | Radboud University Medical Center | 3 | 2013-05-01 | 2020-12-08 |
| An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus Telaprevir, Peginterferon alfa-2b, Ribavirin - Hepatitis C | Phase 1 / Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 42 | 2013-01-01 | 2016-07-20 |
| Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2) - Hepatitis C Infection | Phase 2 | Terminated | MassBiologics | 11 | 2012-11-21 | 2021-02-05 |
| Dose Ranging of GSK2336805 in Combination Therapy GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a - Hepatitis C, Chronic | Phase 2 | Completed | GlaxoSmithKline | 286 | 2012-08-01 | 2017-06-02 |
| VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C VX-222, telaprevir, ribavirin - Chronic Hepatitis C Virus | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 64 | 2012-07-01 | 2014-07-04 |
| A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis VX-222, telaprevir, ribavirin - Chronic Hepatitis C Virus | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 103 | 2012-02-01 | 2014-10-20 |
| An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a - Hepatitis C | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 61 | 2012-02-01 | 2015-06-18 |
| A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C Ribavirin, Mericitabine, Peginterferon Alfa-2a - Hepatitis C | Phase 2 | Completed | Hoffmann-La Roche | 80 | 2011-11-30 | 2017-04-24 |
| Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501 Avatrombopag, Placebo, Pegylated interferon (PEG-IFN) - Thrombocytopenia | Phase 2 | Completed | Eisai Inc. | 65 | 2011-11-01 | 2018-02-22 |
| Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen Telaprevir, pegIFN alfa-2a, Ribavirin - Hepatitis C, Chronic, HIV Infection | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 70 | 2011-04-01 | 2026-04-02 |
| A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection telaprevir, VX-222, ribavirin - Chronic Hepatitis C Virus Infection | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 152 | 2010-08-01 | 2020-09-30 |
| Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose) - Hepatitis C, HIV Infections | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 62 | 2009-10-01 | 2013-10-10 |
| Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV) Telaprevir, Peginterferon alfa-2a, Ribavirin - Hepatitis C | Phase 2 | Completed | Weill Medical College of Cornell University | 15 | 2009-05-01 | 2015-03-20 |
| An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection Telaprevir, Pegylated-interferon-alfa-2a, Placebo - Hepatitis C | Phase 2 | Completed | Tibotec BVBA | 24 | 2008-01-01 | 2013-09-09 |
| Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C MP-424 (Telaprevir) - Hepatitis C | Phase 2 | Completed | Tanabe Pharma Corporation | 15 | 2008-01-01 | 2026-01-06 |
| A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection Telaprevir, Peg-IFN-alfa-2a + Ribavirin (Standard Treatment), Placebo - Hepatitis C, Chronic | Phase 2 | Completed | Tibotec BVBA | 52 | 2007-12-01 | 2013-06-17 |
| A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy Telaprevir, Ribavirin, Pegylated interferon alfa 2a - Hepatitis C | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 117 | 2007-10-01 | 2014-08-05 |
Showing 20 of 25. Sign in to see all of them.
Hepatitis C (14) · Hepatitis C, Chronic (11) · HIV Infections (2) · Depression (1) · Infections (1) · Thrombocytopenia (1)
Vertex Pharmaceuticals Incorporated (11) · Tibotec BVBA (3) · ANRS, Emerging Infectious Diseases (1) · Eisai Inc. (1) · GlaxoSmithKline (1) · Hoffmann-La Roche (1) · MassBiologics (1) · Radboud University Medical Center (1) · Santaris Pharma A/S (1) · Tanabe Pharma Corporation (1) · Timothy Morgan, MD (1) · University of Florida (1) · Weill Medical College of Cornell University (1)
United States (17) · Germany (9) · France (8) · Puerto Rico (6) · United Kingdom (6) · Canada (5) · Netherlands (4) · Spain (4) · Austria (3) · Belgium (3) · Italy (2) · Bulgaria (1) · Japan (1) · New Zealand (1) · Poland (1)
Alireza Manhuchehri (1) · Andrew H. Talal, MD, MPH (1) · David Burger, PharmD, PhD (1) · Fumitaka Suzuki, MD (1) · Michael Hodges, MD (1) · Nathalie Adda, MD (1) · Timothy R Morgan, MD (1)
PMID 19403902, PMID 19403903, PMID 20375406, PMID 21690488, PMID 22387529, PMID 23383655, PMID 23685940, PMID 24811404, PMID 24886541, PMID 24901821, PMID 24982088, PMID 25139963, PMID 25512630, PMID 26752189